IMPORTANT SAFETY INFORMATION Kogenate® FS antihemophilic factor (recombinant) is contraindicated in patients who have life-threatening hypersensitivity reactions, including anaphylaxis to mouse or hamster protein or other constituents of the product. Continue Reading Below   Dear {{accTitle}} {{accFname}} {{accLname}},   {{customText[Thank you for taking time to meet with me to discuss Kogenate FS. You requested some information about Kogenate FS, and I wanted to follow up with some relevant materials. | I’m sorry we missed each other when I stopped by your office. I have some information about Kogenate FS I would like to share with you. | It’s been a while since our last meeting, so I wanted to share some information you might find interesting about Kogenate FS. | Hello, I’m a Bayer HealthCare representative. I would like to share some information with you about Kogenate FS that may be useful for you and your hemophilia A patients. | Although we have not yet had the opportunity to meet in person, I wanted to send you some relevant information about Kogenate FS for your hemophilia A patients. | It was great to see you recently at the NHF meeting. I wanted to share some information you might find interesting about Kogenate FS. | It was great to see you recently at the HFA meeting. I wanted to share some information you might find interesting about Kogenate FS. | It was great to see you recently at the chapter meeting. I wanted to share some information you might find interesting about Kogenate FS. | It was great to see you recently at the community event. I wanted to share some information you might find interesting about Kogenate FS. | It was great to see you recently at the meeting. I wanted to share some information you might find interesting about Kogenate FS.]}}   Factor Solutions offers assistance to help you and your patients navigate difficult insurance issues and find potential sources of financial assistance. Trained case specialists are available to help; call 1-800-288-8374 from 8:30 AM to 5:30 PM (ET), Monday through Friday. Spanish-speaking case specialists are also available.           Factor Solutions can also help patients enroll in the Kogenate FS Co-pay Assistance Program. With this program, eligible patients can be covered for up to $12,000 in co-pay assistance for their Kogenate FS therapy regardless of their income.†   Connect with a Factor Solutions case specialist today: call 1-800-288-8374 or visit factorsolutionssupport.com   For your patients with hemophilia A, Kogenate FS offers:     Joint protection with routine prophylaxis in children with no pre-existing joint damage1     On-demand treatment for active bleeds in adults and children1   For a closer look at the data, visit kogenatefs.com     * The reimbursement helpline does not guarantee your patients will be successful in obtaining reimbursement.   † People with private, commercial health insurance may receive Kogenate FS co-pay or co-insurance assistance, based on eligibility requirements. The program is on a first-come, first-served basis. Financial support is available for up to 12 months. Eligible patients can re-enroll for additional 12-month courses. The program is not for patients receiving prescription reimbursement under any federal-, state-, or government-funded insurance programs, or where prohibited by law. All people who meet these criteria are encouraged to apply.       INDICATIONS     Kogenate® FS antihemophilic factor (recombinant) is a recombinant factor VIII indicated for:   Control and prevention of bleeding episodes in adults and children with hemophilia A.       Surgical prophylaxis in adults and children with hemophilia A.       Routine prophylactic treatment to prevent or reduce the frequency of bleeding episodes in children with hemophilia A and to reduce the risk of joint damage in children without pre-existing joint damage.       Routine prophylactic treatment to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A. Kogenate FS is not indicated for the treatment of von Willebrand disease.   IMPORTANT SAFETY INFORMATION   Kogenate FS antihemophilic factor (recombinant) is contraindicated in patients who have life-threatening hypersensitivity reactions, including anaphylaxis to mouse or hamster protein or other constituents of the product.     Hypersensitivity reactions, including anaphylaxis have been reported with Kogenate FS. Reported symptoms included facial swelling, flushing, hives, decrease in blood pressure, nausea, rash, restlessness, shortness of breath, tachycardia, tightness of the chest, tingling, urticaria, and vomiting. Discontinue Kogenate FS if symptoms occur and seek immediate emergency treatment.     Neutralizing antibodies (inhibitors) have been reported following administration of Kogenate FS predominately in previously untreated patients. Carefully monitor patients for the development of factor VIII inhibitors, using appropriate clinical observations and laboratory tests. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an expected dose, perform an assay that measures factor VIII inhibitor concentration.     Hemophilic patients with cardiovascular risk factors or diseases may be at the same risk to develop cardiovascular events as non-hemophilic patients when clotting has been normalized by treatment with factor VIII.     Serious adverse reactions seen with Kogenate FS are systemic hypersensitivity reactions including bronchospastic reactions and/or hypotension and anaphylaxis, and the development of high-titer inhibitors necessitating alternative treatments to factor VIII.     The most common adverse reactions (>4%) observed in clinical trials were inhibitor formation in previously untreated and minimally treated patients, skin-related hypersensitivity reactions, infusion site reactions, and central venous access device (CVAD) associated infections.       For additional important risk and use information, please click here for full Prescribing Information.   {{customText[I would be glad to provide further information to help you and your hemophilia A patients with their Kogenate FS treatment. If you’d like to speak more, please feel free to contact me at the number below. | Since we haven’t met in a while, I would welcome the opportunity to talk with you in person about this information. If you’re interested, please feel free to contact me at the number below. | Thank you for reviewing this information on Kogenate FS. I hope it was helpful. Please don’t hesitate to call me if you have any questions about the information provided, or if you need additional materials. | Since you requested this information, I want to answer any questions you may have. Please don’t hesitate to call me if there is anything else I can help with. | If you have any questions, I would be happy to speak further, or to set up a visit at your convenience.]}}       Sincerely,   {{userName}} {{User.Phone}} Bayer Hematology         Reference: 1. Kogenate FS with Vial Adapter [package insert]. Tarrytown, NY: Bayer HealthCare LLC; 2014.       Bayer, the Bayer Cross, and Kogenate are registered trademarks of Bayer. © 2014 Bayer HealthCare Pharmaceuticals Inc. All rights reserved.  7/14  KN56005314A   You are encouraged to report negative side effects or quality complaints of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.   Please note: this e-mail is not monitored for replies. If you would like to contact us, please visit our Contact Us section online.     100 Bayer Boulevard, PO Box 915, Whippany, NJ 07981-0915 USA   Privacy Policy                                  Terms and Conditions                                  Unsubscribe